The next major event isn't going to be more clinical trial results. We've just had a clinical trial result and no other clinical trials are underway.
The next major event will be a licensing agreement for AML in a geographic region, including some cash upfront.
This will happen because:
* the AML proofs of concept are now sufficiently complete
* RAC can't perform a loaves and fishes miracle; the cardioprotection and FTO programmes need more cash
* the current SP isn't conducive to a CR.
Why Analysts Believe RAC is “Highly Undervalued”, page-83
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.020(1.20%) |
Mkt cap ! $286.2M | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.68 | $1.61 | $177.8K | 108.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |